Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Viking Therapeutics (0VQA) vs. Competitors

13 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
GB:0VQAViking Therapeutics$26.49$3.34B-4.85-30.11%Strong BuyUnlock the GB:0VQA analyst price target with TipRanks PremiumGB:0VQAUnlock the GB:0VQA top-analyst price target with TipRanks Premium
NAMSNewAmsterdam Pharma Company$19.74$2.33B-11.54-49.27%Strong BuyUnlock the NAMS analyst price target with TipRanks PremiumGB:0VQA vs NAMSUnlock the NAMS top-analyst price target with TipRanks Premium
MLYSMineralys Therapeutics, Inc.$13.78$1.28B-3.16-68.24%Strong BuyUnlock the MLYS analyst price target with TipRanks PremiumGB:0VQA vs MLYSUnlock the MLYS top-analyst price target with TipRanks Premium
GPCRStructure Therapeutics, Inc. Sponsored ADR$17.36$1.24B-4.45-49.68%Strong BuyUnlock the GPCR analyst price target with TipRanks PremiumGB:0VQA vs GPCRUnlock the GPCR top-analyst price target with TipRanks Premium
KLRAKailera Therapeutics, Inc.$11.79$1.58B-3.89-54.65%Strong BuyUnlock the KLRA analyst price target with TipRanks PremiumGB:0VQA vs KLRAUnlock the KLRA top-analyst price target with TipRanks Premium
PBLSParabilis Medicines, Inc.$28.47$3.52B-15.31-9.91%Strong BuyUnlock the PBLS analyst price target with TipRanks PremiumGB:0VQA vs PBLSUnlock the PBLS top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
GB:0VQAViking Therapeutics26.49-9.22-25.82%
NAMSNewAmsterdam Pharma Company19.74-18.88-48.89%
MLYSMineralys Therapeutics, Inc.13.78-28.34-67.28%
GPCRStructure Therapeutics, Inc. Sponsored ADR17.36-19.15-52.45%
KLRAKailera Therapeutics, Inc.11.79-14.21-54.65%
PBLSParabilis Medicines, Inc.28.47-3.13-9.91%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts